INTEGRA LIFESCIENCES HOLDINGS CORP IART

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.

We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT"). The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat ("ENT"). We are the world leader in neurosurgery and one of the top three providers in the U.S. in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about 30% of our overall revenue and focuses on wound reconstruction and care and private label.

Last close 11.91 2026-10-23
Market cap $926.3M 2026-06-30 share count
52-week range 8.70 - 20.49

Valuation FY2025 figures against the last close

P/S0.6x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-6.74

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Asia Pacific
  • Europe
  • Rest of the World
Revenue by geography, 4 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 1.2B (73.7%) 74% United States Asia Pacific, FY2025: 189.3M (11.6%) 12% Asia Pacific Europe, FY2025: 162.7M (9.9%) 10% Europe Rest of the World, FY2025: 78.6M (4.8%) 5% FY2024 United States, FY2024: 1.2B (74.1%) 74% Asia Pacific, FY2024: 176.6M (11.0%) 11% Europe, FY2024: 158.5M (9.8%) 10% Rest of the World, FY2024: 82.7M (5.1%) 5% FY2023 United States, FY2023: 1.1B (71.4%) 71% Asia Pacific, FY2023: 193.1M (12.5%) 13% Europe, FY2023: 165.2M (10.7%) 11% Rest of the World, FY2023: 82.5M (5.4%) 5%
Region FY2025FY2024FY2023
United States $1.20B $1.19B $1.10B
Asia Pacific $189.3M $176.6M $193.1M
Europe $162.7M $158.5M $165.2M
Rest of the World $78.6M $82.7M $82.5M

As the company reported it, from the “SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Major Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Codman Specialty Surgical
  • Tissue Technologies
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Codman Specialty Surgical, FY2025: 1.2B (73.4%) 73% Codman Specialty Surgical Tissue Technologies, FY2025: 434.7M (26.6%) 27% Tissue Technologies FY2024 Codman Specialty Surgical, FY2024: 1.1B (71.0%) 71% Tissue Technologies, FY2024: 466.9M (29.0%) 29% FY2023 Codman Specialty Surgical, FY2023: 1.1B (68.7%) 69% Tissue Technologies, FY2023: 482.6M (31.3%) 31%
Segment FY2025FY2024FY2023
Codman Specialty Surgical $1.20B $1.14B $1.06B
Tissue Technologies $434.7M $466.9M $482.6M

As the company reported it, from the “SEGMENT AND GEOGRAPHIC INFORMATION - Segment Reporting Information (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.64B$1.61B$1.54B$1.56B$1.54B$1.37B$1.52B$1.47B$1.19B$992.1M
Cost of revenue $803.6M$728.5M$656.8M$587.4M$597.8M$520.8M$564.7M$571.5M$435.5M$349.1M
Gross profit $831.6M$882.1M$884.7M$970.3M$944.6M$851.0M$952.9M$900.9M$752.7M$643.0M
R&D ———————$78.0M$63.5M$58.2M
SG&A $699.7M$717.0M$656.6M$616.3M$637.4M$594.5M$687.6M$690.7M$624.1M$455.6M
Total operating expenses $2.13B$1.58B$1.43B$1.32B$1.35B$1.22B$1.42B$1.36B$1.14B$876.7M
Operating income -$493.4M$28.4M$111.5M$238.9M$197.2M$151.4M$93.8M$111.0M$44.8M$115.3M
Interest expense $86.3M$70.6M$51.4M$49.6M$50.4M$71.6M$54.0M$64.7M$35.0M$25.8M
Pre-tax income -$563.5M-$18.2M$81.1M$213.9M$214.7M$93.5M$60.1M$57.4M$11.4M$90.4M
Income tax $47.0M$11.3M$13.3M$33.3M$45.6M$40.4M$9.9M$3.4M$53.4M$15.8M
Net income -$516.8M-$6.9M$67.7M$180.6M$169.1M$133.9M$50.2M$60.8M$64.7M$74.6M
EPS, basic -6.74-0.090.852.182.001.580.590.730.841.00
EPS, diluted -6.74-0.090.842.161.981.570.580.720.820.94
Shares, diluted (wtd. avg.) 76.7M77.0M80.3M83.5M85.5M85.2M86.5M84.0M79.1M79.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $235.0M$246.4M$276.4M$456.7M$513.4M$470.2M$198.9M$138.8M$174.9M$102.1M
Short-term investments $28.7M$27.2M$32.7M$0——————
Receivables $278.8M$272.4M$259.3M$263.5M$231.8M$225.5M$275.3M$265.7M$251.8M$148.2M
Inventory $492.7M$429.1M$389.6M$324.6M$317.4M$310.1M$316.1M$280.3M$296.3M$217.3M
Total current assets $1.16B$1.08B$1.06B$1.16B$1.15B$1.24B$858.2M$775.1M$822.1M$495.2M
Property, plant and equipment $444.3M$405.7M$340.2M$311.3M$311.7M$287.5M$337.4M$300.1M$269.3M$222.4M
Goodwill $615.2M$1.10B$1.06B$1.04B$1.01B$932.4M$954.3M$926.5M$937.9M$510.6M
Other intangibles $1.13B$1.21B$1.07B$1.13B$1.15B$989.4M$1.03B$1.08B$1.16B$561.2M
Total assets $3.60B$4.04B$3.78B$3.89B$3.78B$3.62B$3.30B$3.11B$3.21B$1.81B
Total current liabilities $456.0M$922.1M$307.0M$320.9M$340.0M$401.0M$331.3M$262.6M$348.9M$123.6M
Long-term debt $726.6M$760.5M$775.0M$775.0M$843.8M$877.5M$877.5M$900.0M——
Total liabilities $2.56B$2.49B$2.19B$2.09B$2.10B$2.10B$1.89B$1.73B$2.25B$968.3M
Retained earnings $423.4M$939.9M$946.9M$879.1M$698.6M$532.3M$398.6M$348.4M$285.2M$220.4M
Total equity $1.04B$1.55B$1.59B$1.80B$1.68B$1.51B$1.42B$1.38B$962.3M$839.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $50.4M$129.4M$140.0M$264.5M$312.4M$203.8M$231.4M$199.7M$114.5M$116.4M
Depreciation and amortisation $44.8M$42.4M$40.9M$40.1M$39.4M$42.1M$42.6M$44.1M$88.9M$72.7M
Stock-based compensation $18.6M$24.4M$20.1M$27.7M$36.2M$19.6M$21.3M$20.8M$21.6M$17.3M
Capital expenditure $81.4M$104.4M$66.9M$42.3M$48.0M$38.9M$69.5M$77.7M$43.5M$47.3M
Investing cash flow -$108.1M-$390.8M-$94.2M-$58.6M-$161.4M-$68.1M-$162.7M-$49.7M-$1.22B-$42.6M
Financing cash flow $28.3M$237.9M-$229.9M-$252.0M-$98.2M$121.6M-$8.8M-$180.9M$1.17B-$15.1M
Buybacks $221.0K$52.5M$275.0M$125.0M$0$100.0M$0$0——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000917520-26-000015.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B Revenue, FY2016: 992.1M Gross profit, FY2016: 643M Net income, FY2016: 74.6M Revenue, FY2017: 1.2B Gross profit, FY2017: 752.7M Net income, FY2017: 64.7M Revenue, FY2018: 1.5B Gross profit, FY2018: 900.9M Net income, FY2018: 60.8M Revenue, FY2019: 1.5B Gross profit, FY2019: 952.9M Net income, FY2019: 50.2M Revenue, FY2020: 1.4B Gross profit, FY2020: 851M Net income, FY2020: 133.9M Revenue, FY2021: 1.5B Gross profit, FY2021: 944.6M Net income, FY2021: 169.1M Revenue, FY2022: 1.6B Gross profit, FY2022: 970.3M Net income, FY2022: 180.6M Revenue, FY2023: 1.5B Gross profit, FY2023: 884.7M Net income, FY2023: 67.7M Revenue, FY2024: 1.6B Gross profit, FY2024: 882.1M Net income, FY2024: -6.9M Revenue, FY2025: 1.6B Gross profit, FY2025: 831.6M Net income, FY2025: -516.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $992.1M $1.19B $1.47B $1.52B $1.37B $1.54B $1.56B $1.54B $1.61B $1.64B
Gross profit $643.0M $752.7M $900.9M $952.9M $851.0M $944.6M $970.3M $884.7M $882.1M $831.6M
Net income $74.6M $64.7M $60.8M $50.2M $133.9M $169.1M $180.6M $67.7M -$6.9M -$516.8M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%